ELISpot and FluoroSpot Assay Market

Oxford Immunotec and Cellular Technology Limited (CTL) are leading players in ELISpot and FluoroSpot Assay Market

The ELISpot and FluoroSpot market is expected to reach USD 287 million by 2023 from USD 135 million in 2018, at a CAGR of 16.2%. Growth in this market is largely driven by the rising global incidence of chronic diseases, increasing vaccine development to address the challenge of antimicrobial resistance, and technological advancements in ELISpot and FluoroSpot assay kits and analyzers. The use of FluoroSpot assays for multiple-analyte detection in a single well is also expected to provide opportunities for the growth of the market. On the other hand, the availability of alternative detection technologies is expected to limit market growth during the forecast period.

The ELISpot and FluoroSpot market is consolidated in nature, with a few players offering a variety of products. The major players in this market are Oxford Immunotec (UK), Cellular Technologies (US), Mabtech (Sweden), Becton, Dickinson and Company (US), Abcam (UK), Bio-Techne (US), Autoimmun Diagnostika (Germany), Biotech Investissement (France), Lophius Biosciences (Germany), and U-Cytech (Netherlands).

The key strategies followed by most companies in the ELISpot and FluoroSpot market are product launches and acquisitions. These two strategies accounted for the largest share of the overall growth strategies mapped from 2015 to 2018. Some of the leading players in this market are Oxford Immunotec and Cellular Technology.

To know about the assumptions considered for the study download the pdf brochure

Oxford Immunotec is the leading player in the ELISpot and FluoroSpot market. The company focuses on the development of diagnostic kits for the early detection of diseases such as TB and tick-borne diseases. The company has its presence across the globe and to maintain and improve its presence in the market; Oxford Immunotec adopted both organic as well as inorganic strategies. The company also invests a significant amount on research and development activities. In 2017, it spent around 16% of its revenue on R&D activities, which is higher than most of its counterparts.

Cellular Technology Limited (CTL) is among the pioneers of the ELISpot and FluoroSpot assays. The company developed the first ELISpot analyzers and has been leading the analyzers market ever since. It also offers ELISpot and FluoroSpot kits for detection of multiple analytes. The company’s assay kits are available for the detection of cytokines, antibodies as well as other analytes such as granzymes. The analyzers from CTL are able to detect up to 8 colors.

Related Reports:

ELISpot and FluoroSpot Assay Market by Product (Assay Kit (T Cell and B Cell assay), Analyzer, Ancillary Products), Application (Transplant, Vaccines, Clinical Trials, Cancer), End User (Hospital, Labs, Research Institute) - Global Forecast to 2023

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com

Report Code
MD 6791
Published ON
Dec, 2018
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the ELISpot and FluoroSpot Assay Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
REQUEST A FREE WORKSHOP
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
ONLINE CHAT
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
© MarketsandMarkets Research Private Ltd. All rights reserved